Showing results (51-60 of 56) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Cancer Letters|November 24, 2011
Mammosphere cells from high-passage MCF7 cell line show variable loss of tumorigenicity and radioresistanceGuozhu Xie, Junfang Zhan, Yunhong Tian, et al.Clinical Drug Investigation|October 9, 2025
Efbemalenograstim Alfa, an Fc Fusion Protein, Long‑Acting Granulocyte Colony-Stimulating Factor for Reducing the Risk of Chemotherapy-Induced Neutropenia: Results of a Phase II Randomized, Multicenter, Open‑Label TrialDongmei Ji, Shufang Wang, Wei Yao, et al.BMC Cancer|September 13, 2024
A randomized, multicenter phase III Study of once-per-cycle administration of efbemalenograstim alfa (F-627), a novel long-acting rhG-CSF, for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancerQingyuan Zhang, Zhonghua Wang, Wei Yao, et al.BMJ (Clinical Research Ed.)|October 31, 2023
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Min Yan, Wei Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I TrialHerui Yao, Min Yan, Zhongsheng Tong, et al.The Lancet. Oncology|November 27, 2025
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trialHuiping Li, Jieqiong Liu, Quchang Ouyang, et al.Pageof 6